Xepi
- Generic Name: ozenoxacin cream for topical use
- Brand Name: Xepi
Xepi (Ozenoxacin Cream for Topical Use) side effects drug center
Xepi Side Effects Center
What Is Xepi?
Xepi (ozenoxacin) Cream is a quinolone antimicrobial indicated for the topical treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older.
What Are Side Effects of Xepi?
Common side effects of Xepi include:
- rosacea,
- scaly patches
- and red skin (seborrheic dermatitis).
Dosage for Xepi
Apply a thin layer of dose of Xepi topically to the affected area twice daily for 5 days.
What Drugs, Substances, or Supplements Interact with Xepi?
Xepi may interact with ciprofloxacin or other topical products. Tell your doctor all medications and supplements you use.
Xepi During Pregnancy or Breastfeeding
Tell your doctor if you are pregnant or plan to become pregnant before using Xepi; it is unknown if it would affect a fetus. It is unknown if Xepi passes into breast milk. Consult your doctor before breastfeeding.
Additional Information
Our Xepi (ozenoxacin) Cream, for Topical Use Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
Xepi Consumer Information
Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have:
- any signs of a new skin infection (redness, warmth, swelling, oozing).
Common side effects may include:
- skin redness;
- itching; or
- skin dryness, peeling, or flaking.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Read the entire detailed patient monograph for Xepi (Ozenoxacin Cream for Topical Use)
Xepi Professional Information
SIDE EFFECTS
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety profile of XEPI was assessed in two clinical trials (Trial 1 and Trial 2) in 362 adult and pediatric patients two months of age and older with impetigo. The patients used at least one dose from a 5-day, twice a day regimen of XEPI. Control groups included 361 patients who used placebo and 152 patients who used retapamulin ointment. The median age of the patients enrolled in the clinical trials was 10 years; 3 % of patients were 2 months to less than 2 years of age, 55 % of patients were 2 to less than 12 years of age, 11 % of patients were 12 to less than 18 years of age, and 31 % of patients were 18 years of age or older.
Adverse reactions (rosacea and seborrheic dermatitis) were reported in 1 adult patient treated with XEPI.
Read the entire FDA prescribing information for Xepi (Ozenoxacin Cream for Topical Use)
&Copy; Xepi Patient Information is supplied by Cerner Multum, Inc. and Xepi Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.